Generation Bio Co. (NASDAQ:GBIO) Receives Average Rating of “Hold” from Brokerages

Generation Bio Co. (NASDAQ:GBIO) has earned an average rating of “Hold” from the six analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.00.

GBIO has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Generation Bio in a research report on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a report on Thursday.

Generation Bio Stock Performance

Shares of NASDAQ:GBIO opened at $2.40 on Friday. The business’s 50-day simple moving average is $2.86 and its 200 day simple moving average is $2.89. The company has a market cap of $159.67 million, a P/E ratio of -0.94 and a beta of 2.83. Generation Bio has a one year low of $0.86 and a one year high of $5.50.

Generation Bio (NASDAQ:GBIO) last posted its earnings results on Monday, May 13th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). The firm had revenue of $4.06 million for the quarter, compared to analyst estimates of $3.02 million. Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. Analysts predict that Generation Bio will post -1.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. PFG Advisors acquired a new stake in Generation Bio during the first quarter worth about $41,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Generation Bio during the first quarter valued at approximately $74,000. Panagora Asset Management Inc. acquired a new stake in shares of Generation Bio during the 4th quarter worth approximately $49,000. Kestra Private Wealth Services LLC bought a new stake in shares of Generation Bio in the 4th quarter worth approximately $50,000. Finally, American Century Companies Inc. boosted its position in Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after purchasing an additional 21,167 shares during the period. 95.22% of the stock is owned by institutional investors and hedge funds.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.